Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 07/22 10:00:13 pm
125.03 USD   -0.10%
07/22DJJOHNSON & JOHNS : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNS : Acclarent Unit in $18 Million U.S. Settlement
07/21 JOHNSON & JOHNS : DePuy Synthes Announces Agreement with Materialise..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2012 | 11:11am CEST

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/21 JOHNSON & JOHNSON : DePuy Synthes Announces Agreement with Materialise for 3D-Pr..
07/21 JOHNSON & JOHNSON : tops 2Q forecasts despite profit drop
07/21 Unilever sharpens P&G rivalry by buying Dollar Shave Club
07/20DJJOHNSON & JOHNSON : Jury Acquits Former Johnson & Johnson Unit Executives of Fel..
07/20 JOHNSON & JOHNSON : J&J rises on Wall St. beat, lifts forecast
07/20DJJOHNSON & JOHNSON : Jury Acquits Former Johnson & Johnson Unit Executives of Fel..
07/20 JOHNSON & JOHNSON : Announces Quarterly Dividend for Third Quarter 2016
07/20 Johnson & Johnson Reports 2016 Second-Quarter Results
More news
Sector news : Pharmaceuticals - NEC
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21DJBIOGEN : CEO to Step Down; Reports Upbeat Earnings, Outlook--Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 6 MONTH PORTFOLIO UPDATE : Good News, Double-Digit Increase In Both Income And V..
07/22 DOMINION RESOURCES INC. : An Income Utility Company For The Future But At A Rich..
07/22 JOHNSON & JOHNSON : 3 Reasons To Be Optimistic From The Q2 Results
07/22 Healthcare ratings - upgrades/downgrades
07/21 UNILEVER AND DOLLAR SHAVE CLUB : Delivering A Close, Uncomfortable Shave For Pro..
Advertisement
Financials ($)
Sales 2016 72 055 M
EBIT 2016 21 649 M
Net income 2016 16 531 M
Finance 2016 14 348 M
Yield 2016 2,51%
P/E ratio 2016 21,23
P/E ratio 2017 18,84
EV / Sales 2016 4,57x
EV / Sales 2017 4,29x
Capitalization 343 913 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126 $
Spread / Average Target 0,40%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.53%219 526
ROCHE HOLDING LTD.-9.55%218 832
MERCK & CO., INC.11.36%162 815
BRISTOL-MYERS SQUIBB C..10.02%126 333
More Results